<DOC>
	<DOCNO>NCT02896127</DOCNO>
	<brief_summary>To demonstrate clinical efficacy , safety tolerability secukinumab compare placebo patient ankylose spondylitis Week 16 long term efficacy safety Week 52 .</brief_summary>
	<brief_title>Study Efficacy Safety Secukinumab Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male nonpregnant , nonlactating female patient least 18 year age Diagnosis moderate severe AS prior document radiologic evidence ( xray radiologist 's report ) fulfil Modified New York criterion AS : Active AS assessed BASDAI ≥4 ( 010 ) Baseline Spinal pain measure BASDAI question # 2 ≥ 4 cm ( 010 cm ) Baseline Total back pain measure VAS ≥ 40 mm ( 0100 mm ) Baseline Patients inadequate response failure respond least 2 NSAIDs approve dose minimum 4 week total minimum 2 week NSAID prior randomization , less 4 week therapy withdrawn due intolerance , toxicity contraindication Patients regularly take NSAIDs ( include COX1 COX2 inhibitor ) part AS therapy require stable dose least 2 week randomisation Patients TNFα inhibitor ( one ) must experience inadequate response previous current treatment give approve dose least 3 month prior randomization intolerant least one administration antiTNFα agent Chest Xray MRI evidence ongoing infectious malignant process Patients take high potency opioid analgesic Previous exposure secukinumab biologic drug directly target IL17 IL17 receptor Pregnant nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Ankylosing Spondyloarthritis</keyword>
	<keyword>Axial spondyloarthritis</keyword>
</DOC>